Clinical Trial Update: Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 trial studying serelaxin's effect on hs-cTnI release in chronic heart failure was terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Serelaxin (serelaxin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Heart Failure | Phase 2 | Status: TERMINATED | Results posted: 2018-09-21